FMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fresenius Medical Care AG does not present a compelling buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators are neutral to bearish, options data suggests limited bullish sentiment, and analysts have recently lowered price targets with mixed ratings. While the company's financial performance in Q4 2025 showed strong YoY growth, the forward outlook indicates flat revenue growth and mid-single-digit operating income growth, which limits the stock's upside potential. Given the lack of strong positive catalysts and the absence of Intellectia Proprietary Trading Signals, it is recommended to hold off on investing in this stock at this time.
The MACD is negative and contracting, RSI is neutral at 45.462, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 22.776 and 22.224, while resistance levels are at 24.564 and 25.116. Overall, the technical indicators suggest a neutral to bearish trend.
The company reported strong Q4 2025 financials with significant YoY growth in net income (433.64%) and EPS (454.17%). Additionally, a €1.0 billion share buyback program and a 3% dividend increase were announced.
Analysts have lowered price targets and expressed concerns about headwinds in fiscal 2026, including treatment volume growth below expectations, potential headwinds from the expiry of Affordable Care Act subsidies, and incremental training costs. Technical indicators are neutral to bearish, and options data suggests limited bullish sentiment.
In Q4 2025, revenue increased by 8.82% YoY to €5.9 billion, net income surged by 433.64% YoY to €380.7 million, and EPS grew by 454.17% YoY to €1.33. Gross margin improved by 9.65% YoY to 27.39%. However, the company expects flat revenue growth and mid-single-digit operating income growth in 2026.
Recent analyst ratings are mixed to negative. Morgan Stanley, Deutsche Bank, Citi, and Goldman Sachs have all lowered price targets, with Goldman Sachs downgrading the stock to Neutral from Buy. Analysts cite headwinds in fiscal 2026, including sluggish treatment volume growth and other structural challenges.
